cropper
update
National Cannabis Newswire
update
  • Home
  • Categories
    • news
    • trends
    • insights
    • industry
    • legalization
    • health
    • culture
    • advocacy
    • Brands
    • New Mexico Dispensaries
    • Arizona Dispensaries
April 28.2026
3 Minutes Read

Jersey’s Remarkable Rise: More Cannabis Production Than Colombia!

Confident professional in formal attire by window, related to Jersey Cannabis Supply Chain.

Jersey's Ascendancy as a European Cannabis Powerhouse

The Channel Island of Jersey, a lesser-known entity in the world of cannabis, is emerging as a significant player in the European medical cannabis market, surpassing Colombia in flower supplies to Germany. This astounding achievement, primarily from a single cultivator, Northern Leaf, highlights Jersey's potential as a leading producer of medical cannabis per capita.

With the recent reforms in Germany that partially legalized cannabis usage, the demand for medical prescriptions has skyrocketed, creating a lucrative niche for Jersey's cannabis industry. In the last year alone, Germany's imports of medical cannabis have exceeded 200 tonnes — nearly three times the amounts seen in previous years. Despite an overall slight decline in import volumes, the UK and its territories, particularly Jersey, have increased exports significantly, turning the isle into a vital hub in Europe’s cannabis supply chains.

“A Transformative Growth Story”

Steven Tan, the CEO of Northern Leaf, reflects on the unprecedented growth experienced by Jersey's cannabis sector. Under his leadership, the company has achieved a remarkable turnaround, boosting production capacity and revenue substantially. Tan explains, “We’ve ramped up from producing only a fraction of our potential to operating at 75% capacity, leading to revenues that have quintupled in recent years.” This recovery is a testament to Jersey's unique geographical advantages and rapid regulatory processes.

Geographic and Regulatory Advantages

One of Jersey’s standout features is its quick export permit turnaround and proximity to major European markets. Tan states, “Our permits can be processed faster than anywhere else globally, allowing us to ship products to Germany within 36 hours.” These logistical advantages contribute to maintaining the quality and freshness of the cannabis, fulfilling a critical need in a market where timely access to medical supplies is essential.

Emerging as a Major Export Sector

The Jersey government is positioning medical cannabis as a key export sector, especially as traditional agricultural exports like tomatoes and potatoes decline. A recent report demonstrated that the industry turned a profit for the first time last year, generating over £12 million and attracting significant investments. This growth aligns with Jersey's broader strategy to diversify its economy beyond traditional financial services and agriculture.

The Future of Jersey’s Cannabis Industry

As Jersey stands on the cusp of becoming a premier player in the global cannabis marketplace, challenges remain. High energy costs and regulatory complexities could hinder growth if not addressed effectively. Tan emphasizes the importance of continued government support to navigate these hurdles, which include managing operational costs efficiently.

The potential for Jersey’s cannabis sector to rival the island’s traditional agricultural industries is evident. With Northern Leaf capable of generating significant revenue from minuscule land usage compared to farmers cultivating traditional crops, the future looks bright for Jersey’s cannabis ambitions.

Call to Action: What Lies Ahead for Cannabis Professionals

The future of cannabis supply chains in Europe is changing rapidly, and Jersey is at the forefront of this transformation. For industry professionals looking to capitalize on these developments, staying informed and connected within this evolving landscape is vital. As Jersey stabilizes its place in the market, engaging with local companies and exploring partnerships can open doors to exciting opportunities. Participation in industry events, such as the upcoming Cannabis Europa London, can also provide valuable insights and networking possibilities to stay ahead.

Brands

0 Views

0 Comments

Write A Comment

*
*
Please complete the captcha to submit your comment.
Related Posts All Posts

Agential Cannabis 2026: Unlocking APAC's Medicinal Cannabis Market Potential

Update The Rise of APAC's Medicinal Cannabis Industry In a rapidly evolving landscape, Agential Cannabis 2026 is positioning itself as a key player in APAC’s growing B2B medicinal cannabis marketplace. Scheduled for September 23-24, 2026, at the Bangkok International Trade & Exhibition Centre (BITEC), this dynamic event aims to connect growers, licensed producers, and buyers from across the region. The need for such a focused platform arises as the medicinal cannabis industry transitions from nascent development stages to robust commercial production. Why Thailand Stands at the Forefront The significance of Thailand in the APAC cannabis scene cannot be overstated. In mid-2025, Thailand restructured its cannabis regulations, reinforcing a medical-only model that allowed for greater prescription-based access. This shift has been remarkable, seeing the number of GACP-certified farms doubling to nearly 220 within months. Additionally, 38 cannabis extraction licenses and four export licenses have been granted, identifying Australia as the leading export destination, thus solidifying Thailand's role as a pioneering market within Southeast Asia. Austranna: Innovating Medicinal Cannabis Cultivation Austranna, a Queensland-based licensed cultivator, has been named the headline sponsor of Agential Cannabis 2026. Their CEO, Bryan Ebstyne, emphasizes a commitment to quality and efficiency, detailing plans for a state-of-the-art facility designed for large-scale production. At the event, he will share insights on the integration of automation and robotics into cannabis cultivation, a topic that’s critical as demand for consistency and quality rises. Ebstyne reflects on the importance of gathering industry professionals to engage in meaningful discussions about the future of cannabis in APAC. Empowerment Through Knowledge Sharing The conference program will explore six essential pillars: markets, production, genetics, AI and technology, regulations, and therapeutics. These topics were chosen to provide attendees with practical insights from experienced operators in the field. Featuring over 50 speakers from notable facilities in Canada, Australia, and beyond, delegates will gain valuable expertise on key issues shaping the industry. A Platform for Industry Leaders Agential Cannabis 2026 stands out as a critical nexus for industry leaders, policymakers, and clinicians, facilitating discussions that could shape the future of the medicinal cannabis landscape in APAC. Beyond presentations, the expo will connect local and international buyers, ensuring these operators walk away with new partnerships and knowledge vital for navigating the evolving regulatory environment. Looking Ahead: What to Expect from Agential Cannabis 2026 As APAC's medicinal cannabis landscape grows, events like Agential Cannabis 2026 will be significant in driving the industry forward. With robust participation from various sectors, the expo not only highlights current trends but also offers a glimpse into the future of cannabis in healthcare. This event encapsulates the increasing synergy between policy, production, and technology. For those within the cannabis sector, registration is now open with Super Early Bird rates available until April 30, providing an opportunity for industry professionals to engage with critical insights and innovative practices. Ensure you’re part of this transformative two-day event and join the conversation on the future of medicinal cannabis.

Rescheduling Cannabis to Schedule III: What It Means for Industry Growth

Update A Historic Shift in Cannabis Policy The United States has taken a definitive step towards changing its approach to cannabis, announcing a transition from Schedule I to Schedule III classification under federal law. This pivotal decision, driven by President Trump’s executive order in December 2025, unlocks the potential for significant transformations within the cannabis industry, impacting everything from taxation to health care integration. The Meaning Behind Schedule III For decades, cannabis has been entangled in a web of regulatory constraints, classified alongside substances like heroin under Schedule I of the Controlled Substances Act. This status labeled it with no accepted medical use and a high potential for abuse. However, reclassifying cannabis as a Schedule III substance acknowledges its medicinal properties and significantly alters its place in drug policy. Impact on Cannabis Taxes and Business Operations One of the most immediate effects of this rescheduling is the alleviation of the burdensome Section 280E tax regulations. Currently, cannabis companies face tax rates reaching as high as 70%, as they cannot deduct standard business expenses. This change could pave the way for operators to reduce their tax liabilities and improve cash flow, enhancing their overall financial health and ability to reinvest in growth. A New Era for Medical Research and Insurance Rescheduling cannabis to Schedule III could ease the regulatory hurdles that have historically limited research on its health benefits. With easier access to study cannabis’ efficacy, a potential shift towards more standardized treatments could occur. This might also trigger pilot programs from federal health agencies exploring insurance coverage for medical cannabis, suggesting a pathway for broader acceptance of cannabis in mainstream health care. The Broader Implications of Cannabis Reform This move towards rescheduling isn't just an isolated change; it comes alongside other significant developments in the cannabis landscape. Institutions—and even banks—may now look more favorably on working with cannabis operators, improving access to capital and resources that have previously been elusive due to federal prohibitions. The anticipated flow of institutional investment could revitalize the sector, marking a turning point for budding companies. The Closing of the Hemp Loophole Simultaneously, another regulation banning intoxicating hemp-derived THC products exceeding 0.4mg per serving is set to come into effect in late 2026. While large multi-state operators may find favorable conditions through rescheduling, smaller hemp businesses that thrived on existing loopholes could face existential challenges. Looking Ahead: Cautious Optimism As the rescheduling process unfolds, it is vital for industry stakeholders to approach the future with both optimism and caution. While the change signifies progress, it doesn't legalize cannabis federally or resolve the need for further legislative reforms, particularly regarding banking. Stakeholders must navigate the complex landscape with a mindset geared towards adaptation and resilience. In this evolving landscape, operators, investors, and consumers must remain alert, leveraging opportunities while remaining aware of the remaining challenges. This historic shift marks not just a regulatory change, but also a maturation of the cannabis industry towards a more sustainable and integrated future.

Does the UK Media Represent Public Opinion on Cannabis? The Data Reveals Surprising Insights

Update The Disconnect Between Media Portrayal and Public Perception of Cannabis In recent discussions, a stark contrast has surfaced between how the UK media portrays cannabis and what the general public truly believes. A significant poll from YouGov, conducted between March 31 and April 1, 2026, involved over 2,000 participants and aimed to gauge the sentiments surrounding cannabis usage and legalization. The results are illuminating, revealing that more than a third of adults in Britain (37%) reported having used cannabis, yet the media's ongoing focus on the industry tends to skew perceptions away from this reality. Understanding Public Support for Cannabis Legalization When asked about their views on cannabis legalization, responses reflected a complex landscape of opinions. Approximately 47% of respondents supported legalization, while 43% opposed it. Notably, this divide becomes clearer when respondents were presented with three distinct pathways for cannabis: maintaining it as a criminal offense, decriminalizing it, or full legalization. The poll found that just over a third (35%) favored criminalization, with 33% advocating for legalization and 23% for decriminalization. Political Affiliations and Cannabis Sentiment The YouGov survey further highlighted how political affiliations significantly influence cannabis opinions. For instance, among Conservative voters, a striking 54% supported criminalization, whereas Labour and Liberal Democrat supporters showed more diverse views across all options. This trend demonstrates that public opinion on cannabis is not just a question of personal perception, but is also interwoven with the broader socio-political fabric of the UK. Patient Perspectives and the Medical Cannabis Debate Interestingly, a substantial majority of Britons (57%) perceive cannabis as harmful, with a notable distinction between cannabis and harder drugs. This suggests that while public sentiment remains cautious about cannabis, there is also an understanding of its different classifications within drug policy. Furthermore, 60% of participants believe that making cannabis illegal is ineffective at deterring usage—indicating a significant disconnect between the punitive approach and the realities of public behavior. Moving Towards a Balanced Discussion in Media Recent media narratives have painted a somewhat skewed view of cannabis, often highlighting sensational negative aspects, such as those articulated in recent articles that describe medical cannabis as a "shocking loophole." However, emerging voices like Charlotte Caldwell, who successfully campaigned for medical cannabis legality, now advocate for exploring regulated recreational use as a more comprehensive solution to what some deem a "broken cannabis policy." This evolving conversation suggests that there is room for a more balanced portrayal in the media—one that acknowledges both the risks and benefits of cannabis use. The YouGov data aligns with these changing dynamics, predominantly revealing that over half of the public (56%) would support some form of reforms to cannabis legislation. Conclusion: Bridging the Gap Between Perception and Public Awareness As we reflect on the current media's coverage of cannabis, it becomes crucial for industry professionals and advocates to pursue a dialogue that aligns with public sentiment. Promoting understanding and advocacy based on comprehensive research can significantly bridge the gap between media narratives and the public's evolving perception of cannabis in the UK. Executives and advocates within the cannabis industry must engage with these insights actively to inform their strategies moving forward, focusing on an evidence-based approach that resonates with public opinion, rather than allowing media narratives to dictate the discourse.

Terms of Service

Privacy Policy

Core Modal Title

Sorry, no results found

You Might Find These Articles Interesting

T
Please Check Your Email
We Will Be Following Up Shortly
*
*
*